A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation

Annals of the Rheumatic Diseases

Volumn 71, Issue 12, 2012, Pages 2059-2061

  Cohen, Sophie ^a   Tacke, Carline E ^a   Straver, Bart ^a   Meijer, Natasja ^b   Kuipers, Irene M ^a   Kuijpers, Taco W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; COUMARIN; IMMUNOGLOBULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CASE REPORT; CHILD; CLINICAL FEATURE; CORONARY ARTERY ANEURYSM; CORONARY ARTERY THROMBOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG PULSE THERAPY; ECHOCARDIOGRAPHY; EXTRACORPOREAL OXYGENATION; HEART DILATATION; HUMAN; ISCHEMIA; LETTER; LOW DRUG DOSE; MALE; MEDICAL HISTORY; MUCOCUTANEOUS LYMPH NODE SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PYELONEPHRITIS; RASH; RESPIRATORY FAILURE; RESPIRATORY TRACT INTUBATION; SKIN EXFOLIATION; THERAPY EFFECT; THROMBOSIS PREVENTION; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; SEVERITY OF ILLNESS INDEX;

EID: 84868454230     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201658     Document Type: Letter

References (11)

1. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33.
2. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.
3. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003;4:CD004000.
4. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8.
5. Venugopalan P, Jaya S, Al-Azri MA, et al. Kawasaki disease resistant to immunoglobulin G therapy. Ann Trop Paediatr 2003;23:187-91.
6. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008;153:833-8.
7. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004;163:263-4.
8. Leung DY, Geha RS, Newburger JW, et al. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med 1986;164:1958-72.
9. Leung DY, Cotran RS, Kurt-Jones E, et al. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989;2:1298-302.
10. Maury CP, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med 1988;319:1670-1.
11. Lee Y, Schulte DJ, Shimada K, et al. Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation 2012;125:1542-50.